InVivo Therapeutics Holdings Corp
NVIV
NVIV was delisted on the 12th of February, 2024.
25 hedge funds and large institutions have $2.17M invested in InVivo Therapeutics Holdings Corp in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 3 reducing their positions, and 5 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 3
11% less funds holding
Funds holding: 28 → 25 (-3)
29% less capital invested
Capital invested by funds: $3.04M → $2.17M (-$870K)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
+$123K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$112K |
| 3 |
Renaissance Technologies
New York
|
+$101K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$44.8K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33.6K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$255K |
| 2 |
Millennium Management
New York
|
-$163K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$78.4K |
| 4 |
Goldman Sachs
New York
|
-$57K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$36K |
NVIV Hedge Fund Activity: Q1 2018 in Review
25 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in InVivo Therapeutics Holdings Corp (NVIV) for Q1 2018, worth a combined $2.17M — down 29% from $3.04M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of NVIV and 2 opened new positions — a net loss of 3 holders — while 3 trimmed existing stakes and 3 added.
The largest buyer was Raymond James Financial Services Advisors, adding an estimated $123K. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $255K sold.
- 25 institutional investors held InVivo Therapeutics Holdings Corp (NVIV) as of Q1 2018, down from 28 in Q4 2017.
- Funds reported $2.17M of InVivo Therapeutics Holdings Corp stock for Q1 2018, down 29% quarter-over-quarter.
- 2 funds opened new InVivo Therapeutics Holdings Corp positions in Q1 2018 and 5 closed out, a net change of -3 holders.
- The largest InVivo Therapeutics Holdings Corp buyer in Q1 2018 was Raymond James Financial Services Advisors, an estimated $123K added.
- The largest InVivo Therapeutics Holdings Corp seller in Q1 2018 was Baker Bros. Advisors, an estimated $255K sold.
Based on aggregated 13F filings for Q1 2018.